Q4 2024 Earnings Call Transcript March 27, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.29. Operator: Good morning. And welcome to PDS ...

Clinical Strategy Summary Announced activation of the first site in March 2025 Trial designed to include approximately 350 patients PDS Biotech is aligned with the U.S. Food and Drug Administration ...

Market Open. NCI presentation to highlight IL-12 fused antibody drug conjugate during poster presentation PRINCETON, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq ...

PRINCETON, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq ... Food and Drug Administration (“FDA”) on the design of the registrational trial and clinical ...